Circular RNA Encoding Aquaporin-1 Treats Radiation-Induced Xerostomia In Vivo
Start here
A study published in NEJM on October 22, 2026, by RiboX Therapeutics with the University of Iowa, Johns Hopkins University and the University of Pennsylvania reports the first in vivo delivery of circular RNA encoding Aquaporin-1 to treat radiation-induced xerostomia — the dry-mouth condition that follows radiotherapy in head and neck cancer patients. The work appears in Volume 395, Issue 16, pages 1659-1661. It represents a clinical test of circular RNA, a more stable RNA format than conventional linear messenger RNA, delivered directly to salivary tissue. Full trial results, dosing details, safety outcomes and durability of effect have not yet been reviewed here, as only the abstract was available in the initial publication feed.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- nejm.orgPickIn Vivo Aquaporin-1 Circular RNA Therapy for Radiation-Induced Xerostomia
A study by RiboX Therapeutics with the University of Iowa, Johns Hopkins University and the University of Pennsylvania, published in NEJM Volume 395, Issue 16, pages 1659-1661, reports circular RNA encoding Aquaporin-1 administered in vivo to treat radiation-induced xerostomia; the feed provides only the abstract, with no full text.
Heat trend for this story
Not enough continuous observation yet to draw a trend.